(0.23%) 5 143.50 points
(0.12%) 38 488 points
(0.34%) 17 907 points
(-0.61%) $83.34
(1.92%) $1.960
(-0.16%) $2 343.50
(-0.14%) $27.50
(2.82%) $948.10
(-0.02%) $0.935
(-0.03%) $11.02
(-0.23%) $0.799
(1.88%) $93.60
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.39%
@ $15.52
发出时间: 15 Feb 2024 @ 02:33
回报率: -49.61%
上一信号: Feb 14 - 03:42
上一信号:
回报率: 2.37 %
Live Chart Being Loaded With Signals
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union...
Stats | |
---|---|
今日成交量 | 2.78M |
平均成交量 | 4.57M |
市值 | 1.22B |
EPS | $0 ( 2024-02-15 ) |
下一个收益日期 | ( $0.190 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.210 |
ATR14 | $0.00800 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Denner Alexander J | Buy | 1 662 | Class A Common Stock |
2024-03-08 | John Minardo | Buy | 32 752 | Class A Common Stock |
2024-03-08 | John Minardo | Sell | 32 752 | Performance-based Restricted Stock Unit |
2024-03-08 | Emany Sravan Kumar | Buy | 37 120 | Class A Common Stock |
2024-03-08 | Emany Sravan Kumar | Sell | 37 120 | Performance-based Restricted Stock Unit |
INSIDER POWER |
---|
45.56 |
Last 100 transactions |
Buy: 2 835 189 | Sell: 1 035 601 |
音量 相关性
Ironwood Pharmaceuticals 相关性 - 货币/商品
Ironwood Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $442.74M |
毛利润: | $441.16M (99.64 %) |
EPS: | $-6.45 |
FY | 2023 |
营收: | $442.74M |
毛利润: | $441.16M (99.64 %) |
EPS: | $-6.45 |
FY | 2022 |
营收: | $410.60M |
毛利润: | $409.18M (99.65 %) |
EPS: | $1.130 |
FY | 2021 |
营收: | $413.75M |
毛利润: | $413.75M (100.00 %) |
EPS: | $3.26 |
Financial Reports:
No articles found.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。